drugset / Trial / NCT05536505
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A prospective, multicenter clinical study designed to explore the efficacy of postoperative adjuvant EGFR-TKIs therapy based on MRD status in patients with stage IB-IIIB EGFR-mutant non-squamous non-small cell lung cancer (non-squamous NSCLC). Primary endpoints include 3-year Disease-Free Survival rate (3y-DFS) and median disease-free survival (mDFS).
Timeline
- Start
- 2022-09-13
- Primary completion
- 2025-10-01
- Completion
- 2030-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Icotinib | Small molecule | — | — |
| Subject | Osimertinib | Small molecule | — | — |
Indications
No indication recorded.